Phase 2 Study of Neoadjuvant Pembrolizumab With or Without Radiation for NSCLC

Share this content:
Researchers are assessing the efficacy of neoadjuvant pembrolizumab with or without low-dose SRT among patients with stage I to IIIA NSCLC who plan to undergo surgical resection.
Researchers are assessing the efficacy of neoadjuvant pembrolizumab with or without low-dose SRT among patients with stage I to IIIA NSCLC who plan to undergo surgical resection.

Title: PembroX: Enhancing the Immunogenicity of Non-Small Cell Lung Cancer With Pembrolizumab +/- Stereotactic Radiotherapy Delivered in the Preoperative Window, A Randomized Phase II Study With Correlative Biomarkers1

Principal Investigators: Sue Yom, MD, University of California, San Francisco

Description: For this randomized, open-label phase 2 study, researchers are assessing the efficacy of neoadjuvant pembrolizumab with or without low-dose stereotactic radiation therapy (SRT) among patients with stage I to IIIA non–small cell lung cancer (NSCLC) who plan to undergo surgical resection.

Patients will receive intravenous pembrolizumab 200 mg on day 1 of each 3 week cycle for 2 cycles. Patients in the SRT arm will receive a single 12 Gy dose of SRT within a week of initiating the second cycle of pembrolizumab. Patients will undergo surgical resection within 6 weeks after the last dose of pembrolizumab.

The primary outcome measure of the study is the change in number of infiltrating CD3+ T cells over 25 months. Secondary outcome measures include 1-year overall survival, 1-year relapse free survival, 1-year distant metastases, 25-month progression to unresectability, and 25-month incidence of treatment-related adverse events.

The estimated study enrollment is 40 patients.

For more study information, including exclusion and inclusion criteria, study locations, and contact information, visit https://clinicaltrials.gov/ct2/show/NCT03217071.

Status: Open and recruiting patients as of November 29, 2017.

This study is sponsored by Sue Yom, in collaboration with Merck Sharp & Dohme Corp.

Reference

  1. ClinicalTrials.gov. Pembrolizumab with and without radiotherapy for non-small cell lung cancer. NCT03217071. https://clinicaltrials.gov/ct2/show/NCT03217071 . Accessed November 29, 2017.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters